← FDA DRUG APPROVALS

FDA ANDA · ANDA075673

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

Sponsor: TARO

APPLICATION
ANDA075673
TYPE
ANDA
ORIGINAL APPROVAL
2001-05-29
LATEST ACTION
2020-07-06
ROUTE
TOPICAL
DOSAGE FORM
CREAM
MARKETING STATUS
Prescription

Products

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATEPrescription
BETAMETHASONE DIPROPIONATE EQ 0.05% BASE, CLOTRIMAZOLE 1% · CREAM · TOPICAL

Approval history

2020-07-06Labeling · Supplement 18 · standardAP
2020-07-06Labeling · Supplement 15 · standardAP
2020-07-06Labeling · Supplement 21 · standardAP
2009-01-29Labeling · Supplement 10AP
2004-06-23Labeling · Supplement 6AP
2004-06-23Labeling · Supplement 9AP
2002-04-11Labeling · Supplement 1AP
2001-05-29OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →